Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by the destruction of insulin-producing β-cells in the pancreas by cytotoxic T-cells. To date, there are no drugs that can prevent the development of T1D. Insulin replacement therapy is the standard care for patients with T1D. This treatment is life-saving, but is expensive, can lead to acute and long-term complications, and results in reduced overall life expectancy. This has stimulated the research and development of alternative treatments for T1D. In this review, we consider potential therapies for T1D using cellular regenerative medicine approaches with a focus on CRISPR/Cas-engineered cellular products. However, CRISPR/Cas as a genome editing tool has several drawbacks that should be considered for safe and efficient cell engineering. In addition, cellular engineering approaches themselves pose a hidden threat. The purpose of this review is to critically discuss novel strategies for the treatment of T1D using genome editing technology. A well-designed approach to β-cell derivation using CRISPR/Cas-based genome editing technology will significantly reduce the risk of incorrectly engineered cell products that could behave as a “Trojan horse”.
Multiple myeloma (MM) is a clonal malignancy of plasma cells that remains largely incurable despite major advances in proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Chimeric antigen receptor (CAR)-engineered immune cells have transformed the therapeutic landscape, but CAR-T cell therapy faces challenges such as severe cytokine release syndrome (CRS), neurotoxicity, limited persistence, and logistical complexity. In recent years, natural killer (NK) cells have emerged as a promising platform for next-generation cellular immunotherapy, offering innate antitumor activity, a reduced risk of graft-versus-host disease (GvHD), and the feasibility of “off-the-shelf” allogeneic production. This review summarizes current advances in CAR-NK cell therapy for MM, focusing on two major aspects: the diversity of cell sources—including NK-92, peripheral (PB) and cord blood (CB), and induced pluripotent stem cell (iPSC)-derived NK cells—and the expanding repertoire of target antigens such as BCMA (B-cell maturation antigen), NKG2D, CD38, CD70, SLAMF7, CD138, and GPRC5D. We highlight preclinical and early clinical studies demonstrating potent cytotoxicity, favorable safety profiles, and innovative multi-targeting strategies designed to overcome antigen escape and enhance persistence. Emerging clinical data suggest that CAR-NK cell therapy may combine the specificity of CAR recognition with the inherent safety and versatility of NK biology, offering a potential paradigm shift in the treatment of relapsed or refractory MM. Further clinical validation will determine whether CAR-NK cell therapy can achieve durable remission and complement or surpass current CAR-T modalities.
Adrenocortical cancer (ACC) is a rare malignant neoplasm originating from the adrenal cortex, presenting limited therapeutic options. An avenue for improving therapeutic efficacy may involve a deeper understanding of the role of adrenocortical stem/progenitor cells in the pathogenesis of this disease. Although existing data suggest stem/progenitor characteristics in certain cell populations within ACC, the challenge remains to identify adrenocortical stem cell markers directly involved in its carcinogenesis. In our study, we aimed to identify multipotency markers such as LGR5 and CD90 in various ACC types to confirm their presence and localization. The study included tumor tissue samples from 13 patients with ACC treated at the Endocrinology Research Centre (Moscow, Russia) between 2005 and 2023. We conducted immunohistochemical analyses to identify the aforementioned markers and examined the association between their expression and clinico-morphological parameters. Our pilot study results demonstrate the presence of LGR5- and CD90-positive tumor cells in all samples. Despite the small sample size, we observed statistically significant differences in disease-free survival based on the number of CD90-positive cells. These findings suggest a potential diagnostic, prognostic, and predictive value of cancer stem cell markers, underscoring the need for their further analysis in a larger cohort of patients with ACC.
Adrenocortical cancer (ACC) is a rare malignant neoplasm originating from the adrenal cortex, presenting limited therapeutic options. An avenue for improving therapeutic efficacy may involve a deeper understanding of the role of adrenocortical stem/progenitor cells in the pathogenesis of this disease. Although existing data suggest stem/progenitor characteristics in certain cell populations within ACC, the challenge remains to identify adrenocortical stem cell markers directly involved in its carcinogenesis. In our study, we aimed to identify multipotency markers such as LGR5 and CD90 in various ACC types to confirm their presence and localization. The study included tumor tissue samples from 13 patients with ACC treated at the Endocrinology Research Centre (Moscow, Russia) between 2005 and 2023. We conducted immunohistochemical analyses to identify the aforementioned markers and examined the association between their expression and clinico-morphological parameters. Our pilot study results demonstrate the presence of LGR5- and CD90-positive tumor cells in all samples. Despite the small sample size, we observed statistically significant differences in disease-free survival based on the number of CD90-positive cells. These findings suggest a potential diagnostic, prognostic, and predictive value of cancer stem cells markers, underscoring the need for their further analysis in a larger cohort of patients with ACC.
One approach to therapeutic cancer vaccine development uses whole tumor cells or their lysates as sources of a broad repertoire of tumor antigens. A key advantage of this strategy is that it does not require prior identification of tumor antigens, unlike personalized neoantigen peptide or mRNA vaccines, potentially reducing the time and cost of vaccine development. However, late-phase clinical trials have not demonstrated sufficient efficacy of tumor cell-based cancer vaccines. Currently, strategies to enhance the therapeutic potential of vaccines based on whole tumor cells and their derived lysates are being actively developed, and the vaccine potential of individual tumor cell components, such as cell membranes and extracellular vesicles, is under investigation. In this review, we systematize data on how whole tumor cells and their derivatives (lysates, cell membranes, and extracellular vesicles) are used to generate therapeutic cancer vaccines, analyze the results of experimental and clinical studies, and evaluate promising engineering and combination therapy strategies capable of overcoming the current limitations of this platform.
1 August 2024 in Russian Journal of Developmental Biology
Maturity-onset diabetes of the young type 10 (MODY10) is inherited in an autosomal dominant manner, characterized by islet cell dysfunction, impaired insulin synthesis and secretion. MODY10 is relatively rare, and is caused by a mutation of the 11p15.5 site on chromosome 11 encoding insulin. We obtained iPSCs (ERCi003‑A line) from dermal fibroblasts derived from a patient with MODY10 carrying a previously undescribed pathogenic heterozygous mutation in the INS gene (с.93С>G, p.C31W) into iPSCs using transfection with self-replicating RNA vector. iPSCs proliferate in dense monolayer cell colonies, have a normal karyotype (46,XY), express pluripotency markers (OCT4, SOX2, TRA-1-60). The functional pluripotency of iPSCs was confirmed by their ability to form embryoid bodies and differentiate into the three germ layers (ecto-, endo-, and mesoderm). Sanger sequencing of iPSCs confirmed the presence of pathogenic heterozygous mutation in the INS gene. This cell line could be useful to thoroughly modeling of MODY10 to improve clinical understanding of the disease.